medigraphic.com

2006, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2006; 73 (1)

Immunomodulators and Aphrodite

Gustavo Acosta Altamirano, María del Rocío Reyes Montes, Maribel Hernández Rodríguez, Luís Enrique Nava Martínez, Fernando Octavio Pinacho

Language: Spanish
References: 23
Page: 22-27
PDF size: 91.00 Kb.


ABSTRACT

Introduction. During the development of pregnancy, in the maternal immune system immunosuppressive factors are generated to avoid the rejection of proteins of paternal origin, reason why immunosuppressive chorionic proteins and leucocyte products present in peripheral blood are synthesized, umbilical cord and human colostrum that inhibit replication of virus VIH and neoplastic cells. Material. Colostrum leukocytes PMN and milk are, mainly, neutrophils that vary in size, present vacuoles and fat grains in cytoplasm and its nucleus is eccentric; at electronic microscope multilobular with peripheral chromatin condensation are observed. Conclusion. Immunosuppressives are produced in pregnant women and immediate puerperium, reason why we denominate femenine specific immunosuppressives or aphrodite immunosuppressives.


REFERENCES

  1. Ojeda OM, Fernandez Ortega C, Araña RJ. Dializable leukocyte extract supresses the activity of essential transcription factor for HIV-1 gene expression in unstimulated MT-4 cells biochemical and biophysical research communications 273 (2000); 1099-1103.

  2. Ojeda MO, van’t Veer C, Fernandez Ortega CB, Arana Rosainz M de J, Buurman WA. Dialyzable leukocyte extract differentially regulates the production of TNF-alpha, IL-6, and IL-8 in bacterial component-activated leukocytes and endothelial cells. Inflamm Res 2005; 54(2): 74-81.

  3. Ojeda Ojeda M, Fernandez Ortega CB, Arana Rosainz MJ. Dialysable leucocyte extract (DLE) reduces lipopolysaccharide-induced tumour necrosis factor secretion in human leucocytes. Biotherapy 1996; 9(1-3): 163-70.

  4. Acosta G, Ortiz J, Barragán L, Torres S, Santos JL. Linfocitos T CD4 y CD8 en calostro y sangre autóloga de mujeres mexicanas. Inmunología (España) 1994; 13: 118-21.

  5. Acosta G, Ortiz J, Nateras E, Rocha LM y cols. Inmunología de calostro y leche humana. Enf Infecciosas y Microbiol (Méx) 1992; 12: 293.

  6. Inmunología de las mucosas. México, D.F.: Distribuidora y Editorial Mexicana (DEMSA); 1992.

  7. Sandoval ZS, Berrospe GGA, Becerril PJ, García GR, Vargas HV, Acosta AG. Efecto inhibitorio del calostro humano sobre Vibrio cholerae 01. Rev Hosp Jua Mex 2001; 68(2): 63-7.

  8. Fernandez OC, Dubed M, Ramos Y, Navea L, Alvarez G, Lobaina L, Casillas D, Rodriguez L. Non-induced leukocyte extract reduces HIV replication and TNF secretion biochemical and biophysical research communications 325 (2004); 1075-81.

  9. Fujisawa T, Yamaguchi Y, Kimura H. Transfer factor in restoration of cell mediated immunity in lung cancer patients. Jpn J Surg 1983; 13(4): 304-11 (ISSN: 0047-1909).

  10. Khan A, Sellars W, Grater W, Graham MF, Pflanzer J, Antonetti A, Bailey J. Hill The usefulness of transfer factor in asthma associated with frequent infections. Ann Allergy 1978; 40(4): 229-32 (ISSN: 0003-4738).

  11. Liubchenko TA, Holeva OH, Kholodna LS, Stepanchuk VA, Vershyhora AIu. Human specific transfer factor to Staphylococcus aureus antigens [Liuds’kyij spetsyfichnyij Faktor perenosu do antyheniv Staphylococcus aureus.] Fiziol Zh 1997; 43(3-4): 25-32.

  12. Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. Immunodiagnosis and immunotherapy. Biotherapy 1996; 9(1-3): 67-72.

  13. Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti G, Cavallari A. Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy. Biotherapy 1996; 9(1-3): 117-21.

  14. Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy 1996; 9(1-3): 13-6.

  15. Hennen WJ. Transfer factor, natural immune booster Woodland Publishing; 1998.

  16. Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med 2000; 6(4): 332-41.

  17. Farmer JL, Rosenberg JS, Hester RB, Gottlieb AA.Counter inhibitor: a low molecular weight cytokine derived from human leukocyte dialysates reverses antigen dependent PMN and macrophage migration inhibition. Int Arch Allergy Appl Immunol 1984; 73(2): 146-50.

  18. Viza D. AIDS and transfer factor: myths, certainties and realities. Biotherapy 1996; 9(1-3): 17-26.

  19. Pizza G, De Vinci C, Fornarola V, Palareti A, Baricordi O, Viza D. In vitro studies during long-term oral administration of specific transfer factor. Biotherapy 1996; 9(1-3): 175-85.

  20. De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D. Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): A preliminary report. Biotherapy 1996; 9(1-3): 133-8.

  21. Ablashi DV, Levine PH, De Vinci C, Whitman JE Jr, Pizza G, Viza D. Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports. Biotherapy 1996; 9(1-3): 81-6.

  22. Ferrer AVE, Mendoza HL, Hidalgo LH, et al. Factor de transferencia. Una alternativa de tratamiento de las infecciones por virus del herpes en pacientes con sida. Rev Med Hosp Gen Mex 1995; 58(4): 148-50.

  23. Huerta López José Guadalupe. Factor de transferencia: Una alternativa en el tratamiento de las enfermedades alérgicas. Rev Alerg Asma Inm




2020     |     www.medigraphic.com